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Abstract
Approximately one billion people are infected with hookworms and/or blood flukes (schistosomes) in devel-
oping countries. These two parasites are responsible for more disability adjusted life years lost than most other
neglected tropical diseases (NTDs), and together, are second only to malaria. Although anthelmintic drugs are
effective and widely available, they do not protect against reinfection, resistant parasites are likely to emerge,
and mass drug administration programs are unsustainable. Therefore, there is a pressing need for the devel-
opment of vaccines against these parasites. In recent years, there have been major advances in our under-
standing of hookworms and schistosomes at the molecular level through the use of ‘‘omics’’ technologies. The
secretomes of these parasites have been characterized using transcriptomics, genomics, proteomics, and newly
developed gene manipulation and silencing techniques, and the proteins of interest are now the target of novel
antigen discovery approaches, notably immunomics. This research has resulted in the discovery, development,
and early stage clinical trials of subunit vaccines against hookworms and schistosomes.
Introduction
The genomics revolution has enormous implications forpublic health (Burke et al., 2010). In this review we focus
on recent advances in the ‘‘omics’’ for neglected tropical dis-
eases (NTDs), and discuss how these advances will facilitate
the development of new and sustainable control methods for
NTDs. Hookworms and blood flukes (schistosomes) are some
the most important parasites of humans in terms of their
global health impact on children, pregnant women, and
people engaged in subsistence farming (Hotez et al., 2008a,
2008b). Together, their disease burdens exceed those of all
other NTDs (Hotez et al., 2010). Because hookworms and
schistosomes typically impact human health without result-
ing in mortality, they have not gotten the full attention of the
global health policymakers and have not been prioritized ei-
ther for large-scale control efforts or for research funding.
However, when the chronic morbidities due to hookworm
disease and schistosomiasis are fully considered based on
disability-adjusted life years (DALYs) lost, these diseases to-
gether rank among the most important in developing coun-
tries, resulting in an annual loss of between 4.5 and 92 million
DALYs (Hotez et al., 2010; King and Dangerfield-Cha, 2008).
Both infections/diseases can be treated with anthelmintic
drugs, but this approach does not protect against the high
frequency of reinfection with the parasites (Hotez et al., 2010).
Moreover, single-dose mebendazole has been shown to ex-
hibit poor efficacy for hookworm and after repeated ad-
ministration in the same endemic population (Keiser and
Utzinger, 2008), efficacy has been reported to diminish over
time (Albonico et al., 2003), raising concerns about possible
drug resistance. Indeed, drug failures have arisen with
benzimidazoles in livestock (Geerts and Gryseels, 2000).
Importantly, the mainstay of control for schistosomiasis is
the quinoline compound, praziquantel (PZQ). There are
concerns that mass administration of PZQ is unsustainable
because of lower than expected efficacies of single-dose PZQ,
and high rates of reinfection after treatment, pointing toward
the potential emergence of anthelminthic drug resistance
(Clements et al., 2009). Indeed, PZQ resistance has already
been documented in Schistosoma mansoni in the laboratory
(Fallon and Doenhoff, 1994). Mass drug administration
programs are therefore inadequate in isolation, cannot hope
to advance global elimination efforts, and new tools and
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integrated approaches are needed to ensure sustainable
control of schistosomiasis (Gray et al., 2010). Vaccines are an
essential component for the long-term control, elimination,
or eradication of infectious diseases. Here, we describe the
use of various ‘‘omics’’ approaches to characterize the tran-
scriptomes, genomes, proteomes, and glycomes of schisto-
somes and hookworms, as well as the postgenomic
molecular applications of these data to identify the most
suitable target antigens for vaccine development to combat
the diseases they cause.
The Parasites
Hookworms
Human infections with hookworms occur predominantly
in areas of rural poverty in developing countries (Hotez et al.,
2004). An estimated 600–700 million people are infected with
hookworms worldwide, mostly in sub-Saharan Africa, South
America, and parts of Asia, notably Indonesia, Bangladesh,
and India. Approximately 85% of hookworm infections are
caused by Necator americanus, with the remainder caused by
Ancylostoma duodenale (Hotez et al., 2004). The infective stage
is the microscopic, infective larva (third-stage larva or L3),
which lives in the soil until it comes in contact with human
skin. Larvae actively penetrate the skin and migrate within
the afferent vasculature to the lungs where they ascend the
pulmonary tree to the pharynx, are swallowed, and molt to
become adult male and female worms (approximately 1 cm in
length). Adult hookworms attach to the mucosa and sub-
mucosa of the small intestine where they rupture capillaries
and arterioles and feed on the extravasated blood (Brooker
et al., 2004). The subsequent steps in the acquisition of the
hookworm’s blood meal are a major target of current vacci-
nomic strategies and will be discussed in this review. Almost
all of the pathological effects andmorbidity due to hookworm
infections result from intestinal blood loss (Hotez et al., 2004).
Female and male hookworms mate in the small intestine, the
female releases microscopic eggs that exit the body in host
feces. The eggs hatch in the environment, releasing first-stage
larvae, which feed on bacteria and other organic debris in the
soil before they molt twice to develop through to the en-
sheathed L3 stage.
Schistosomes
In contrast, schistosome flatworms (platyhelminths), also
known as trematodes or flukes, cause approximately 207
million cases of human schistosomiasis worldwide, mostly in
sub-Saharan Africa (Steinmann et al., 2006). However, some
estimates indicate that as many as 400 million people are af-
fected (King, 2010). In Africa, Schistosoma haematobium is the
most prevalent human schistosome; it causes urinary tract
schistosomiasis, comprising approximately two-thirds of the
world’s cases of schistosomiasis, whereas S. mansoni is the
principal cause of intestinal schistosomiasis and is responsible
for approximately one-third of all cases. S. mansoni also causes
schistosomiasis in Latin America, with most of the cases oc-
curring in Brazil, while S. japonicum and S. mekongi cause
approximately one million cases of intestinal schistosomiasis
in East Asia (Steinmann et al., 2006). Schistosomiasis is
transmitted through contact with freshwater containing the
infective free-swimming microscopic cercariae, which like
hookwormL3, actively penetrate the skin of their human host.
Cercariae that have entered human skin shed their tails to
become schistosomula, which enter the vasculature and lungs
before relocating to the venous system where they become
sexually mature adults, pair, then mate, and egg production
begins (Gryseels et al., 2006). Adults of S. haematobiummigrate
to the venous plexus that drains the bladder and reproductive
organs, whereas, for example, S. mansoni and S. japonicum
migrate to the mesenteric veins draining the intestine (Gry-
seels et al., 2006). Female schistosomes produce eggs, each
equipped with a spine that helps to facilitate penetration
through blood vessels and into the urinary tract and geni-
tals (S. haematobium) or intestine and liver (S. mansoni and
S. japonicum). Much of the pathological effects from schisto-
somiasis are a result of the immune response to parasite eggs
trapped in host tissues during chronic infection. The resulting
granulomata become fibrotic, which in turn, results in severe
circulatory impairment in the affected organs (Pearce and
MacDonald, 2002). In both Brazil and in sub-Saharan Africa
coinfections with hookworms and schistosomes are com-
monly encountered (Hotez et al., 2010).
Genomics and Transcriptomics
Schistosomes
Draft genome sequences were recently published for
S. mansoni and S. japonicum (Berriman et al., 2009; The Schis-
tosoma japonicum Genome Sequencing and Functional
Analysis Consortium, 2009). There is very little annotated
sequence data available for S. haematobium, despite it being
widely considered as the most important of the schistosome
species in terms of prevalence and pathogenicity (Rollinson,
2009). For the purposes of this review, we will focus primarily
on S. mansoni. The haploid S. mansoni genome is approxima-
tely 363Mb in size and contains almost 12,000 genes, dis-
tributed across seven autosomal plus sex chromosome pairs
(ZW in the female and ZZ in the male) (Berriman et al., 2009).
Prior to the sequencing of the genomes, comprehensive
transcriptomic datasets (Verjovski-Almeida et al., 2003) and
genetic maps (Criscione et al., 2009) were published, provid-
ing scaffolds with which to assemble the genome sequences.
DNA microarrays have been generated by multiple groups
and utilized to explore transcriptional profiles of different
developmental stages of the parasite (Fitzpatrick et al., 2009;
Gobert et al., 2009b, 2010; Jolly et al., 2007) (Fig. 1) and the
transcriptional effects of different treatments (Gobert, 2010;
Gobert et al., 2010). Fitzpatrick and colleagues (Fitzpatrick
et al., 2009) conducted a thorough characterization of schis-
tosome development using statistical and network-based
exploratory analyses, and highlighted key transcriptional
changes associated with life cycle progression and identified
numerous candidate molecules for drug and vaccine devel-
opment, including membrane spanning proteins, such as the
G-protein coupled receptors and tetraspanins.
Schistosomes are acoelomate organisms (i.e., which lack a
defined body cavity), and have parenchymal tissues sur-
rounding their organs, making the manual dissection of or-
gans or organ systems difficult. Recent advances in laser
microdissection microscopy (LMM), however, has allowed
researchers to start to assemble a gene atlas for schistosomes,
whereby the transcriptional profiles of defined schistosome
tissues or organs have been delineated using a combination of
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LMM to isolate defined tissues for RNA extraction, followed
by microarray analysis to specifically identify the most
abundant transcripts in tissues of interest (Gobert et al.,
2009a). This approach has proven particularly relevant for the
selection of antigens for vaccine and drug development. LMM
has been used successfully to dissect the gut and other tissues
of S. japonicum (Gobert et al., 2009a), allowing for the identi-
fication of 147 genes that were upregulated in the gastroin-
testinal tract of the adult female worm. Given that
schistosomes reside in the vasculature and ingest blood as a
source of nutrition, the gut of the parasite is considered to be a
vulnerable tissue to target for vaccine development. Numer-
ous proteolytic enzymes (proteases) were among the most
highly expressed genes in gut tissues. Given their central roles
in the proteolysis of haemoglobin and serum proteins
(Brindley et al., 2001; Caffrey et al., 2004; Delcroix et al., 2006),
these enzymes are likely to be critical for survival and, thus,
worthy vaccine targets. Indeed, at least one of these proteases
has been shown to be essential for the development of worms
in vitro and survival in vivo using gene silencing approaches
(Morales et al., 2008), more of which will be discussed later in
the section on postgenomic applications. Recently, we used a
microarray for S. mansoni to identify the most abundant
transcripts inmaturing schistosomula (Gobert et al., 2010), the
developmental stage of the parasite that is widely considered
to be the most vulnerable to the immune response against the
parasite (McManus and Loukas, 2008). The most highly up-
regulated genes included a tetraspanin (Sm-tsp-3—one of the
genes also highlighted by Fitzpatrick et al., 2009), which is
known to be expressed in the outer apical membrane of the
parasite (Braschi and Wilson, 2006), and was 1,600-fold up-
regulated during the first 5 days of schistosomula develop-
ment; intestinal proteases belonging to distinct mechanistic
classes were also highly upregulated, including orthologues
of some proteases of S. japonicum that were highly expressed
in gut tissue (Gobert et al., 2009a).
S. haemtobium is the most prevalent of the human schis-
tosomes and is arguably the most problematic in terms of
human morbidity, leading in many cases to squamous cell
carcinoma of the bladder (Steinmann et al., 2006). Alar-
mingly, a recent report revealed that S. haematobium and a
cattle schistosome, S. bovis, have hybridized in the Senegal
River Basin in Africa, and hybrid parasites have been de-
tected in human urine and feces, prompting fears of an
emerging pathogen that might display hybrid vigor, in-
cluding enhanced pathogenesis (Huyse et al., 2009). Despite
its importance, there is a dearth of genomic and tran-
scriptomic information for S. haematobium, hampering efforts
to develop vaccines for this organism. Rollinson (2009) elo-
quently emphasized the need to promote research on
S. haematobium in order to control it effectively, but the
research community has been slow to adopt this species as
the priority for research due to its reduced tractability in
laboratory animal model studies.
FIG. 1. Percentage of Schistosoma mansoni genes encoding for secreted/membrane proteins that underwent equal to or more
than twofold increased expression in each category. Categories included 3-h-old versus 5-day-old schistosomula in the
presence or absence of red blood cells (RBC). All genes that were upregulated were screened for the presence of a signal
peptide or anchor using the SignalP Web server; those ORFS with a signal peptide/anchor were then further screened for
transmembrane (TM) domains using TMPred. The tables show the 10 most highly upregulated genes in each category.
Reproduced from Gobert et al., 2010b.
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Hookworms
Currently, there is limited genomic sequence available for
any hookworm species, although sequence surveys have been
reported for the zoonotic canine hookworm, Ancylostoma
caninum (Abubucker et al., 2008). However, substantial EST
data exists for at least three different species—the major hu-
man hookworm, N. americanus, and the zoonotic canine
hookworms, A. caninum and A. ceylanicum. Recently, deep
sequencing approaches have resulted in the assembly of al-
most 20,000 contigs from N. americanus adult worm ESTs
(Cantacessi et al., 2010) and up to 93% coverage of the A.
caninum larval and adult stage transcriptomes (Wang et al.,
2010). These results have allowed the comparative analysis of
the N. americanus and A. caninum transcriptomes, revealing
both qualitative and quantitative differences in transcription
(Cantacessi et al., 2010). For example, transcripts encoding
for protease inhibitors were inferred to be highly represented
in N. americanus, whereas SCP/Tpx-1/Ag5/PR-1/Sc7 (SCP/
TAPS), also referred to as Pathogenesis Related Proteins
(PRPs) were predominant in A. caninum. Interestingly, the
PRP family accounted for 17 of the 30 most highly upregu-
lated geneswhenA. caninum L3made the transition from free-
living to parasitic (Datu et al., 2008). Indeed, one of these PRPs
from N. americanus, called Na-ASP-2, is the only hookworm
protein to date to have entered into a phase I clinical trial
(Bethony et al., 2008).
Hookworms, like schistosomes, are relatively large, mul-
ticellular pathogens. However, unlike schistosomes, hook-
worms have a pseudocoelome, with easily discerned organs
that float within a pressurized body cavity, which allows
their removal using various traditional and microscopy-
based dissection approaches. LMM was used to dissect
the gut and reproductive organs of N. americanus and
A. caninum, followed by RNA extraction and construction of
tissue-specific cDNA libraries for subsequent sequencing
(Ranjit et al., 2006). This approach yielded a snapshot of the
intestome of these hookworms and identified a suite of
molecules with proven or potential roles in digestion of
the blood meal, including aspartic (Loukas et al., 2005;
Williamson et al., 2002) and cysteine proteases (Loukas et al.,
2004), putative hemolysins (Don et al., 2004), and peptide
transporters (Hotez et al., 2010). Proteins involved in
the digestion of the blood meal are a major target for vaccine
development within the Human Hookworm Vaccine
Initiative (Hotez et al., 2010; Loukas et al., 2006; Pearson
et al., 2010), and we are currently focusing on candidate
molecules that have been identified using a range of ‘‘omics’’
approaches.
Proteomics
Schistosomes
Various tissues and fluids from schistosomes have been
characterized using a range of proteomic approaches. Of
particular relevance to vaccine development is the elucidation
of the tegument surface proteome of the adult blood fluke.
The schistosome tegument is a syncitium and acts as the direct
interface between the host and the parasite, and as such,
contains extracellular proteins—Skelly and Wilson (2006)
have provided a highly comprehensive review on the schis-
tosome tegument. Many vaccine antigens that are located in
the tegument have been tested in murine models of schisto-
somiasis, but only a few are likely to be available to antibodies
on the surface of a live, intact parasite. DeMarco and
Verjovski-Almeida (2009) recently reviewed the use of pro-
teomics to identify schistosome proteins for vaccine antigen
and drug discovery. We have thus restricted our discussion
here to studies that focus on the outer membrane proteins of
the schistosome tegument, primarily because we believe that
exposed membrane proteins are likely to be the most effica-
cious as vaccine antigens (Loukas et al., 2007; McManus and
Loukas, 2008).
By labeling the surface of live adult S. mansoniwith biotin,
only primary amine groups that were exposed on the outer
surface of the tegument incorporated the label, allowing for
their purification via streptavidin affinity chromatography
and characterization by liquid chromatography tandem
mass spectrometry (LC-MS/MS) (Braschi andWilson, 2006).
Surprisingly, few proteins were detected on the surface of
the live parasite, reflecting an epithelium that is relatively
depauperate in surface exposed proteins. This finding,
however, limits the number of target vaccine antigens to a
manageable number. Indeed, where tested, these outer
membrane proteins have conferred good levels of protection
in mice and are recognized preferentially by antibodies from
resistant people in Brazil (Cardoso et al., 2006, 2008; Tran
et al., 2006). A similar study was conducted using biotiny-
lated S. japonicum, but instead of excising bands from a one-
dimensional gel for protein extraction, Mulvenna and col-
leagues (2010) used an off-gel electrophoresis technique to
minimize protein loss during sample preparation and sub-
sequently identified orthologues of the S. mansoni-labeled
proteins as well as additional membrane spanning proteins
of interest (Fig. 2).
Parasitic helminths secrete a barrage of molecules into
host tissues as they migrate, feed, and produce eggs within
their hosts. One component linked to this process at the host–
parasite interface is the excretory/secretory (ES) proteins—
molecules that are released from live helminths maintained
in tissue culture. The presumption that proteins released
in vitro mimic or at least resemble the suite of proteins re-
leased in vivo is contentious, and this is particularly evident
in the ES proteome of schistosome cercariae, where of 48
spots detected on a 2D-gel, 29 were thought to originate in
the secretory vesicles and 18 from the cytosol of the secretion
glands, with the latter thought to be due to holocrine secre-
tion (Curwen et al., 2006). This controversy is further
highlighted by the fact that only approximately half of the
proteins in the ES products from adults of S. japonicum were
putatively secreted (based on their gene ontologies) and
some of the most abundant proteins detected are of known
intracellular origin (Liu et al., 2009).
After schistosome cercariae penetrate the skin and trans-
form into schistosomula, they enter the vasculature and mi-
grate (depending on species) to the portal or bladder vessels
via the lungs. The first 3 to 5 days of this migratory process
between the skin and the lungs is thought to represent the
most susceptible stage to antibody-mediated killing (El Ridi
and Tallima, 2009; McManus and Loukas, 2008; Mountford
et al., 1995). Neither the tegument nor ES proteins from in vitro
cultured or in vivo obtained schistosomula have been char-
acterized to date, primarily due to the difficulty in obtaining
sufficient quantities of material for such protein studies, but
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such studies are highly anticipated and would be decidedly
instructive for future selection of immunogens.
Hookworm ES proteome
Schistosomes and hookworms belong to very different
phyla and have distinct morphologies and physiological
processes, despite sharing some similarities in biology, such
as host entry (percutaneous) and feeding (on blood). Unlike
ES products from schistosomes, the ES products of adult
hookworms consist mostly of bona fide secreted proteins
complete with signal peptide sequences. Using a strategy
combining the traditional technology of one-dimensional
SDS-PAGE and the newer fractionation capabilities of OFF-
GEL electrophoresis, 105 ES proteins were identified from the
adult blood-feeding stage of A. caninum (Mulvenna et al.,
2009). Highly represented among the identified proteins were
carbohydrate-binding lectins and a number of proteases be-
longing to the three major classes: aspartic, cysteine, and
metalloproteases. In hematophagous helminths, many pro-
teases are secreted from the intestine (nematodes) or gastro-
dermis (trematodes), where they act to degrade host
hemoglobin and serumproteins as part of the feeding process.
These proteases are therefore exposed to components of the
immune system of the host when the parasite ingests blood
and thus represent potential targets for the development of
vaccines; see review by Pearson et al. (2010).
Of the A. caninum ES proteome, 28% of the proteins iden-
tified thus far represent PRP familymembers (Cantacessi et al.,
2009; Mulvenna et al., 2009), supporting the massive expan-
sion of this gene family in the hookworm genome and their
overrepresentation among upregulated genes in larvae dur-
ing the transition to parasitism (Datu et al., 2008). Other
protein families identified to date include hyaluronidases,
FIG. 2. Pictorial representation of the biotinylation of the surface of live Schistosoma japonicum adult worms after perfusion
from mice, and subsequent processing of labeled surface proteins for proteomic analysis. The micrograph in the top right
corner shows detection of the biotinylated surface of the parasite using confocal micsoscopy. The slide was stained with Cy3-
anti-biotin (red) and DAPI to locate nuclei (blue). Biotin was detected in the surface layer of the tegument (TEG), where it
appears as a bright sinuous band of label. Positive immunoreactivity was also detected in regions subjacent to the surface
layer (arrowheads), reflecting the presence of biotin in interconnecting bridges, and in discrete regions in sub-muscle cells
(long arrows), likely to be tegumentary cytons. Figure modified and reproduced with permission from Mulvenna et al., 2010.
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lysozyme-like proteins, and transthyretin-like proteins, all of
which are vaccine candidates but have yet to be assessed for
efficacy in animal models.
Hookworm intestome
Targeting the hookworm gut for vaccine development has
shown to be a worthwhile pursuit (Hotez et al., 2010; Loukas
et al., 2006). Other blood-feeding parasites, including the
barber’s pole worm of livestock (Haemonchus contortus) and
the cattle tick (Rhipicephalus microplus), are effectively killed by
vaccine-induced antibodies against native proteins and pro-
tein complexes derived from the guts of these parasites (Smith
et al., 1994). Indeed, the gut of adult H. contortus possesses a
tightly bound multiglycoprotein complex that is rich in di-
gestive proteases and protease inhibitors (Knox and Smith,
2001), and effective silencing of some of these genes af-
fects parasite development, survival, and fecundity in vivo
(Samarasinghe et al., 2011). It is not known whether the
orthologous hookworm proteases form a similar complex to
H-gal-GP, but, with the development of techniques such as
LMM (Jones et al., 2004; Xu, 2010) and tissue profiling via
mass spectrometry, the characterization of proteins in mi-
croscopic tissues, such as a hookworm gut, is now a possi-
bility. Indeed, one of the lead hookworm vaccine antigens is
the intestinal haemoglobinase, Na-APR-1 (a cathepsin D-like
aspartic protease), where the protective effect appears to es-
tablish neutralizing antibodies that inhibits substrate prote-
olysis (Loukas et al., 2005; Pearson et al., 2009).
Glycomics
The role of helminth glycans as protective antigens is a
complex but extremely important area. Helminths are eu-
karyotes and therefore decorate proteins that enter the se-
cretory pathway with an array of glycan moieties. For a
review on this topic, see Nyame et al. (2004). The difficulty in
purifying or synthesizing large quantities of helminth glycans
has thus far precluded their widespread use in helminth
vaccine trials. However, glycans are the basis for some highly
effective antibacterial vaccines (Huang and Wu, 2010), and
some of the most highly protective proteins from parasitic
helminths are indeed glycosylated. For example, the H-gal-
GP and H11 antigen complexes from H. contortus are heavily
glycosylated, a feature that permitted their initial purification
and identification of native protein via lectin affinity chro-
matographies (Knox and Smith, 2001). Where they have been
characterized at the molecular level, helminth glycans offer
great promise as vaccine candidates (Cummings and Nyame,
1999; Harrison et al., 2008; Maass et al., 2009).
Postgenomics
Schistosomes
One of themost revolutionary advances in the postgenomic
era for the study of parasitic helminths is gene silencing by
RNA interference (RNAi). Parasitic helminths, by virtue of
their often complex life cycles and large genomes, have ren-
dered themselves refractory to many genetic manipulation
tools that allow the exploration of gene function (Mann et al.,
2008, 2010). RNAi is now widely used to assess gene function
in schistosomes, and appears to be particularly effective for
genes expressed in tissues readily accessible to dsRNA, such
as the tegument and gastrodermis (Krautz-Peterson et al.,
2010; Stefanic et al., 2010). RNAi has been used to confirm
gene function for a number of potential schistosome vaccine
antigens and drug targets, and helps explain how some vac-
cines, which are based on these proteins, might exert their
efficacy. RNAi was used to show that the tetraspanin,
Sm-TSP-2, plays important structural roles impacting tegu-
ment development, maturation or stability, and is essential
for survival in vivo (Tran et al., 2010). Silencing of the genes
encoding gastrodermal proteases of S. mansoni, including
cathepsin D (Morales et al., 2008), papain-like cysteine pro-
teases, and asparaginyl endopeptidase (Delcroix et al., 2006)
has confirmed the roles of these proteases and the order in
which they cleave their substrates during the multienzyme
digestive cascade of haemoglobin. The ability to silence a
schistosome gene aswell as assess the effect in vitro and in vivo
prompted us to suggest that the lethality of silencing a
schistosome gene be one of the critical steps in ranking anti-
gens for progress toward clinical trials for a human schisto-
somiasis vaccine (Hotez et al., 2010).
Its obvious utility notwithstanding, RNAi leads to only
transient gene silencing and, in addition, may be inaccessible
to some developmental stages and/or tissues of schistosomes.
RNAi mediated by short hairpin-RNA (shRNA) expressing
transgenes can induce specific and long-term knock down in
eukaryotic cells (Paddison et al., 2004). In vivo, for example,
vector-based, RNAi approaches that lead to integration of
transgenes encoding cassettes that express short interfering
RNAs can circumvent deficiencies with exogenous RNAi by
providing continuous and/or conditional gene silencing
(Sliva and Schnierle, 2010). In addition to vector-based RNAi,
transgenesis offers the potential to endow other desirable
phenotypes including the expression or coexpression of hel-
minth or host antigens. Both vector-based RNAi and expres-
sion of foreign transgenes have begun to be deployed in
studies with schistosomes, with potential outcomes including
validation of putative vaccine candidates and even the over-
expression of candidate antigens. Pseudotyped murine leu-
kemia virus and the piggyBac transposon have both been
shown to transduce developmental stages of schistosomes,
leading to chromosomal integration of retroviral transgenes
and transgene reporter activity (Kines et al., 2008; Morales
et al., 2007; Yang et al., 2010). Moreover, a vector-based RNAi
approach has been reported in which the MLV transgene
encoded a long hairpin RNA specific for a schistosome pro-
tease involved in hemoglobinolysis (Tchoubrieva et al. 2010).
Hookworms
There are limited reports of the application of RNAi to
hookworms. The technique has been used to silence (by
soaking) the expression of some genes in the L3 stage of the
related blood-feeding nematode, H. contortus (Geldhof et al.,
2006; Kotze and Bagnall, 2006; Samarasinghe et al., 2011;
Zawadzki et al., 2006). Successful silencing of genes in para-
sitic nematodes is plagued by a lack of reproducibility be-
tween and even within laboratories (Viney and Thompson,
2008). However, recently, Samarasinghe et al. (2011) showed
that the proximity of the tissue expressing the mRNA of in-
terest to the dsRNA being applied played a role in the success
of RNAi inH. contortus. They showed that genes for intestinal
proteases (and lead vaccine antigens) could be silenced in
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feeding third-stage larvae by soaking parasites in dsRNA.
Presumably the oral uptake of this RNA afforded direct ex-
posure to the intestinal cells expressing the mRNAs. On the
other hand, genes that were expressed in tissues that were not
easily accessible to ingested dsRNA were not susceptible to
RNAi by soaking. The dsRNA-treated larvae were then used
to infect sheep, and silencing of intestinal proteases, such as
the aminopeptidase H11, resulted in reduced survival of adult
worms and reduced fecundity of female worms that did
survive. The ability to silence the expression of intestinal
protease genes inH. contortus is a major advance in the area of
vaccine antigen discovery for blood-feeding nematodes of
livestock and humans—it allows, for the first time, an as-
sessment of the function(s) of these proteases in vivo, and,
therefore, their roles in parasite survival can potentially be
addressed. For example, questions regarding functional re-
dundancy in pathways that involve multigene families, such
as the intestinal cysteine proteases of Haemonchus ( Jasmer
et al., 2001) and hookworms (Ranjit et al., 2008), can be ad-
dressed.
Like RNAi, transgenesis has yet to be reported in hook-
worms. However, progress has been reported with gene
manipulation of the related parasitic nematode, Strongyloides
stercoralis, in which transgene approaches developed for use
in Caenorhabditis elegans have been employed to demonstrate
that morphogenesis of infective L3 from earlier larval forms
requires the DAF-16 orthologue FKTF-1, a forkhead tran-
scription factor that regulates dauer larval development in C.
elegans (Castelletto et al., 2009).
Immunomics
The availability of the S. mansoni and S. japonicum genomes
coupled with the proteomic characterization of the tegument
and ES products has provided researchers with the tools re-
quired to apply postgenomic approaches to vaccine antigen
discovery. The availability of high throughput protein ex-
pression techniques, such as in vitro translation using pro-
karyotic or eukaryotic ribosomes, and sera from resistant
humans and animals (e.g., hyperinfected rats or animals vac-
cinated with irradiated cercariae), means that schistosomiasis
researchers are now armed and ready to utilize immunomic
approaches. Recently, we designed and manufactured the first
Schistosoma immunomics protein microarray (Driguez et al.,
2010) and are currently using it as a vaccine discovery tool
(Fig. 3). The proteins selected for inclusion on the chip in-
cludes those from previously published proteomic data and
in silico screening of available sequences to identify potential
immunogens based on protein location, with a particu-
lar emphasis on proteins expressed on/in the tegument.
Following cloning, selected sequences were expressed in a
cell-free expression system and contact-printed on to nitro-
cellulose coated microscope slides to form microarrays. The
arrays have been probed with IgG (different subclasses)
and IgE from resistant and chronically infected humans and
animals (S. Gaze et al., unpublished). The approach will allow
us to identify antigens that are the major target of protective
IgG responses while avoiding antigens that might induce
potentially harmful IgE responses when administered as
vaccines (Hotez et al., 2010). This innovative technology of
reverse vaccinology has the potential to transform vaccine
research for schistosomiasis and other parasitic diseases of
humans and animals.
The only protein microarray containing proteins derived
from parasitic helminths that we are aware of is the schisto-
some array described above. Immunomics, however, holds
great potential for accelerating antigen discovery for vaccine
programs targeting other parasitic helminths, such as hook-
worms. Animals can be protected against hookworm disease
by vaccination with irradiated L3 (Loukas et al., 2006; Miller,
1978), but only one study has attempted to identify the major
targets of antibodies from this sera using a panel of only three
existing recombinant antigens derived from L3 (Fujiwara
et al., 2006). The transcriptomes of human and canine hook-
worms have been well characterized (Cantacessi et al., 2010;
Wang et al., 2010), paving the way for the development of
hookworm protein microarrays for antigen discovery. As for
schistosomiasis vaccine antigen discovery, antigens that
FIG. 3. Schematic depiction of the use of immunomics to develop and screen a Schistosoma protein microarray for screening
with sera from resistant and chronically infected humans and animals.
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progress toward clinical trials need to be the target of a pro-
tective IgG response, while avoiding potentially deleterious
IgE responses, thus warranting a pipeline of hookworm vac-
cine antigen discovery and production. Immunomics provi-
des an ideal tool by which to discover and conduct early
screening for up- and down-selection of proteins for progress
toward clinical trials.
There are, of course, inherent problems with many high-
throughput approaches, and immunomics is no exception.
One of the major challenges with developing vaccines against
eukaryotic pathogens, such as helminths, is the faithful rep-
lication of vaccine antigens using recombinant technologies.
Given that many helminth vaccine antigens are extracellular,
they are processed through the secretory pathway and often
undergo complex posttranslational processing and are ex-
tensively disulfide bonded. We routinely express helminth
secreted proteins in yeast or insect cells to obtain properly
folded recombinant protein. Cell-free protein expression sys-
tems, whether they be components of prokaryotic or eu-
karyotic cells, do not possess the cellular machinery to process
secreted proteins and will not always faithfully reproduce the
correct fold. Nonetheless, the high-throughput nature of this
expression system lends itself well to immunomic studies and
has proven to be an excellent tool for identifying antigens
from a range of single celled pathogens at least (Crompton
et al., 2010; Davies et al., 2008; Eyles et al., 2007).
Conclusions
Major advances in biotechnology occur at a staggering
pace. We can now sequence the genome and proteome of a
complex pathogen in a matter of weeks or even days. For
some pathogens, we can knock genes in and out of the ge-
nome and silence mRNA expression, and we can now syn-
thesize a pathogen proteome and spot it on to a chip in an
array. High throughput technology for antigen discovery no
longer seems to be a barrier to developing vaccines for most
pathogens, yet the number of new vaccines that have been
developed during this genomic/postgenomic era is still rela-
tively low. This might just reflect the long time required to
take findings from the bench to the bedside and the funding
issues that plague this ‘‘valley of death’’ transition. However,
the (apparent) lack of success also suggests that a shotgun
approach to characterizing the molecular composition of an
organism is only one part of the story in vaccine development.
Colossal obstacles still face vaccinologists, particularly those
working on parasitic helminths. They include the difficulties
in expressing large numbers of cDNAs in eukaryotic expres-
sion vectors and identifying laboratory animal models suit-
able for high throughput testing. For instance, hookworm
antigens cannot routinely be tested in a mouse challenge
model. Thus, the successes identified for reverse vaccinology
approaches for bacterial vaccines against Streptococcus and
Meningococcus (Rappuoli and Covacci, 2003) are not expected
to promote eukaryotic parasite vaccine development anytime
soon. Moreover, it is generally accepted that antihelminth
vaccines will need to be multivalent (given that distinct de-
velopmental stages of helminths have very different tran-
scriptomes and proteomes) and will require at least two shots
to confer sufficient protection (Loukas et al., 2006, McManus
and Loukas, 2008). Once we have used a suite of omics tech-
nologies to identify the best vaccine antigens, how do we
formulate, optimize and deliver them? These are the big
questions that now face us in the development of vaccines.
The data and information provided through the use of
‘‘omics’’technologies can now be harnessed using hypothesis-
driven bench research approaches in our quest to develop as
effective antischistosome and antihookworm vaccines as are
currently available for the taeniid cestodes (Gauci et al., 2005).
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